The effect of Wistar RA 27/3 live attenuated rubella virus vaccine, given subcutaneously, was evaluated in 30 susceptible female schoolteachers aged 20 to 35 years and over, from the city of São Paulo, Brazil. The serum samples, to be tested for hemagglutination-inhibiting (HI) and complement fixing (CF) antibodies, were collected 10, 30, 90 and 180 days after vaccination. Of the 30 susceptible adults who received the Wistar RA 27/3 vaccine, 96,6% showed seroconversion in the HI and CF tests. No unusual reactions occured.
Rubella vaccine; Hemagglutination inhibition tests; Complement-fixation tests